CHRS

Coherus BioSciences Inc.

Price

$1.44

return (12m)

22.30%

p/e

-1.60

p/bv

3.46

DIVIDEND YIELD

0.00%

CHRS price

Coherus BioSciences

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CHRS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-0.13%

3 months

-9.24%

1 year

22.30%

2 years

6.11%

5 years

-90.84%

10 years

-95.15%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals CHRS

Valuation

P/E

-1.60

Sector -4.26

Industry -4.26

P/BV

3.46

Sector 2.11

Industry 2.11

P/Revenue (PSR)

4.14

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

1.10

Sector 1.25

Industry 1.25

P/Net Current Assets

61.10

Sector -5.47

Industry -5.47

P/Working Capital

3.62

Sector -1.10

Industry -1.10

EPS

-0.85

Sector -1.94

Industry -1.94

BVPS

0.39

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

68.92%

Sector 38.90%

Industry 38.90%

EBITDA Margin

0.00%

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

0.00%

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

-100.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

-100.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.07

Sector 0.03

Industry 0.03

Profitability

ROE

-217.18%

Sector -61.50%

Industry -61.50%

ROA

-69.11%

Sector -63.85%

Industry -63.85%

ROIC

0.00%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

1.77

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

0.00

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.32

Sector 0.43

Industry 0.43

Liabilities/Assets

0.68

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-31.04%

Sector -

Industry -

5Y Earnings CAGR

-14.38%

Sector -

Industry -

Fundamentals CHRS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CHRS Coherus BioSciences Inc.	$1.44	26.59%	0.00%	-1.60	3.46	-217.18%	-100.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CHRS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Coherus BioSciences

Coherus BioSciences Inc.

Average Investor10 user rating

4.0 (2 people)

United States

16 years

Founded: 2010

2014

Time since IPO - 12 years

291

Employees

Coherus BioSciences Inc. (United States) is listed on the Nasdaq and has a market capitalization of $210.80 million, with shareholders equity totaling $60.84 million.

The company employs approximately 291 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Coherus BioSciences Inc. reported $50.94 million in revenue, generating net income of $-132.13 million.

Key financial metrics include a P/E ratio of -1.60, a price-to-book (P/B) ratio of 3.46, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CHRS.

Market cap

$210.80 million

Net worth

$60.84 million

$60,840,000.00

Assets

$191.18 million

$191,180,000.00

Total Shares Outstanding

155.00 million

155,000,000

Average Daily Trading Volume

$1.04 million

$1,039,341.38

Sector

Health Care

Industry

Biotechnology

CHRS

CHRS revenue and profits

Financial Results CHRS

DRAG THE FRAME TO SEE MORE DATA

CHRS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Coherus BioSciences (CHRS) today?

A cotação de Coherus BioSciences (CHRS) hoje está em US$ 1.44, com uma variação de 22.3% em relação ao último ano. A cotação de Coherus BioSciences (CHRS) iniciou o ano negociando na casa dos US$ 1.42 e hoje está em US$ 1.44. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Coherus BioSciences (CHRS) e dados de ações do Ibovespa e mercados internacionais.

Quando Coherus BioSciences (CHRS) paga dividendos?

Coherus BioSciences (CHRS) não distribuiu dividendos no último ano.

Is Coherus BioSciences (CHRS) a good investment?

Atualmente, Coherus BioSciences (CHRS) está cotada a US$ 1.44, com um P/L de -1.60, representando um desvio de 36% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 22.3 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 22.30%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Coherus BioSciences (CHRS) stock?

Investir em ações de Coherus BioSciences (CHRS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Coherus BioSciences (CHRS) yield today?

A rentabilidade de Coherus BioSciences (CHRS) foi de -0.13% no último mês, 22.30% no último ano e -90.84% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Coherus BioSciences (CHRS) hoje, o investimento total seria de US$ 144.31, com base na cotação atual de US$ 1.44.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 176.49
Em 5 anos: US$ 13.22
Em 10 anos: US$ 7.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CHRS

Coherus BioSciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CHRS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CHRS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Coherus BioSciences

Coherus BioSciences Inc.

United States

16 years

2014

291

PROFIT X PRICE CHRS

Financial Results CHRS

CHRS cash flow

Asset, Revenue and Profit Growth - CHRS

CHRS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions